Santen launches DIQUAS Ophthalmic Solution in Japan

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that DIQUASTM Ophthalmic Solution 3% (diquafosol tetrasodium) received pricing approval and was launched for sale today in Japan by its partner, Santen Pharmaceutical Co., Ltd. Inspire will receive a related milestone payment of $1.25 million in the fourth quarter of 2010 and is also entitled to receive payments based upon a tiered royalty rate on net sales of DIQUAS in Japan, with a minimum rate in the high single digits and a maximum rate in the low double digits.

"We are pleased that DIQUAS is now available as a new treatment option for dry eye patients in Japan," said Adrian Adams, President and CEO of Inspire. "We are completing this year with continued strong operational momentum. In addition to the DIQUAS launch and milestone payment, as a result of our prudent cash flow management throughout 2010, we recently paid off our term loan facility and expect to end the year with a strong balance sheet with no debt. This provides a solid foundation as we enter a potentially transformational year in 2011, beginning with the anticipated first quarter release of results from TIGER-2, our second Phase 3 trial of denufosol tetrasodium for cystic fibrosis."

Pursuant to an agreement between the companies, Santen may develop and commercialize diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases, such as dry eye disease, in Japan and nine other Asian countries. Diquafosol tetrasodium is currently in Phase 3 clinical testing by Santen in China.

Source:

Inspire

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Santen Pharmaceutical Co., Ltd.. (2020, February 01). Santen launches DIQUAS Ophthalmic Solution in Japan. News-Medical. Retrieved on July 24, 2024 from https://www.news-medical.net/news/20101213/Santen-launches-DIQUAS-Ophthalmic-Solution-in-Japan.aspx.

  • MLA

    Santen Pharmaceutical Co., Ltd.. "Santen launches DIQUAS Ophthalmic Solution in Japan". News-Medical. 24 July 2024. <https://www.news-medical.net/news/20101213/Santen-launches-DIQUAS-Ophthalmic-Solution-in-Japan.aspx>.

  • Chicago

    Santen Pharmaceutical Co., Ltd.. "Santen launches DIQUAS Ophthalmic Solution in Japan". News-Medical. https://www.news-medical.net/news/20101213/Santen-launches-DIQUAS-Ophthalmic-Solution-in-Japan.aspx. (accessed July 24, 2024).

  • Harvard

    Santen Pharmaceutical Co., Ltd.. 2020. Santen launches DIQUAS Ophthalmic Solution in Japan. News-Medical, viewed 24 July 2024, https://www.news-medical.net/news/20101213/Santen-launches-DIQUAS-Ophthalmic-Solution-in-Japan.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension